RLX vs VEEV: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
VEEV is the larger of the two ($49.18B market cap): the incumbent the market prices for continued execution (29.60x forward earnings, beta 0.88). RLX is the smaller challenger ($1.91B), cheaper on forward earnings (9.58x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
RLX vs VEEV: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | RLX | VEEV | What it tells you |
|---|---|---|---|
| Market cap | $1.91B | $49.18B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 9.58 | 29.60 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 14.23 | 49.79 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 1.11 | 0.88 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 0% of range | 87% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 0.83 | 6.61 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: RLX is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how RLX and VEEV affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. RLX and VEEV share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined RLX and VEEV exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does RLX Technology (RLX) do?
RLX Technology Inc. designs and sells closed-system e-vapor devices and pods, plus a growing disposable line, under the RELX brand. It began as the dominant player in China's domestic vaping market, then was reshaped almost overnight when Beijing imposed a national product standard in 2022 that banned non-tobacco flavors, created a licensing regime and layered on a 36% consumption tax. Domestic revenue fell hard. Management responded by pushing the business overseas, and international markets across Europe, Southeast Asia and elsewhere now carry the growth, at 68.5% of revenue in the June 2026 quarter. Manufacturing is largely outsourced to Chinese contract producers, so the company operates asset-light, with brand, product design and channel relationships as the assets that matter.
What does Veeva Systems (VEEV) do?
Veeva Systems Inc. is the dominant provider of cloud software built specifically for the life-sciences industry, serving pharmaceutical, biotech, and medical-device companies. Its products span two broad areas: commercial applications, including its CRM used by drug-company sales and medical teams, and its Vault platform, a content and data-management system used across clinical trials, regulatory submissions, quality, and safety. Because Veeva's software is purpose-built for the highly regulated life-sciences world and is deeply embedded in customers' core workflows, it enjoys strong retention and pricing power, and it earns recurring subscription revenue.
RLX vs VEEV: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- RLX drivers: International expansion carrying the growth; Margin recovery and operating leverage.
- VEEV drivers: Life-sciences market dominance; Vault CRM transition.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Regulation is the dominant risk and it arrives from multiple directions at once: China's flavor ban, licensing regime and 36% consumption tax already reset the domestic business, and overseas the UK, France and several EU states have moved against disposables while flavor restrictions spread. For VEEV, the dominant risk is valuation: as a high-quality software company, Veeva trades at a premium multiple (about 51x trailing earnings, 30x forward and roughly 14.5x sales in October 2026, after a ~64% three-month rally that took the stock above the ~$297 average analyst target) that assumes durable growth, so any slowdown in revenue or the Vault CRM migration could pressure the stock.
RLX or VEEV: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick RLX if you believe its drivers more; VEEV if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the RLX and VEEV guides.
RLX vs VEEV: the full fundamentals
RLX. RLX reports in renminbi; the dollar figures above are approximate conversions and will shift with the exchange rate. The trailing multiple of roughly 16 times looks ordinary until the cash is netted out, at which point the operating business is being valued at close to nothing, with the stock at about 0.9 times book. Whether that discount is an opportunity or a fair price for regulatory and jurisdictional risk is the entire argument over the stock. Figures reflect results through the June 2026 quarter and market data as of October 16, 2026; third-quarter results follow on November 13.
VEEV. Figures are approximate as of October 16, 2026; verify live numbers before acting. Veeva has real earnings, so investors look at its P/E (about 51x trailing and 30x forward) alongside revenue growth of roughly 17-18%, a near-30% operating margin and free cash flow. After a ~41% year-to-date rise the stock carries a premium valuation that embeds steady growth, a successful Vault CRM transition and expanding AI adoption, so the shares can fall on any growth disappointment. The next quarterly report is expected around late November 2026, with consensus near $2.34 of EPS on ~$935 million of revenue.
Headline figures (approximate, October 2026): RLX shows market cap ~$2.1B (ADS ~$1.74, Oct 16, 2026), revenue (last four quarters) ~RMB 4.9B; Q2 2026 RMB 1.01B (~$149M), up ~15%, gross margin (q2 2026) ~35.4% (vs ~27.5% a year earlier), net income (ttm) ~RMB 985M (~$145M); VEEV shows revenue (ttm) ~$3.46 billion, q2 fy2027 revenue ~$928 million, up ~17.6% YoY, net income (ttm) ~$1.0 billion (~29% net margin), operating margin ~30%.
The bottom line: RLX vs VEEV
RLX and VEEV are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined RLX and VEEV exposure against your real portfolio. It is not an investment adviser.
Wondering how RLX or VEEV fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about RLX Technology
Ask Walnut's AI anything about RLX and see how it fits what you own.
FAQ
What is the difference between RLX and VEEV?
+
RLX Technology Inc. Veeva Systems Inc. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is RLX or VEEV the better stock?
+
Neither is universally better. VEEV is the larger incumbent; RLX is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, RLX or VEEV?
+
On forward P/E (as of November 2026), RLX trades at 9.58x and VEEV at 29.60x, so RLX is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both RLX and VEEV?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of RLX vs VEEV?
+
RLX: Regulation is the dominant risk and it arrives from multiple directions at once: China's flavor ban, licensing regime and 36% consumption tax already reset the domestic business, and overseas the UK, France and several EU states have moved against disposables while flavor restrictions spread. Excise taxes on vapor products are rising in most markets RLX sells into, and youth-vaping enforcement can close a channel with little notice. As a Cayman Islands holding company with operations in China, the ADR carries the usual structural exposures, including audit-inspection and delisting politics under US-China tensions, limited recourse for minority holders, and dual-class voting that concentrates control with founder Kate Wang. Competition from cheap disposable brands and from the reduced-risk portfolios of the global tobacco majors pressures both price and shelf space. Results are reported in renminbi, so currency moves affect dollar returns independently of how the business performs, and the free float is small enough that the shares can move sharply on modest volume. VEEV: The dominant risk is valuation: as a high-quality software company, Veeva trades at a premium multiple (about 51x trailing earnings, 30x forward and roughly 14.5x sales in October 2026, after a ~64% three-month rally that took the stock above the ~$297 average analyst target) that assumes durable growth, so any slowdown in revenue or the Vault CRM migration could pressure the stock. Veeva's fortunes are concentrated in a single industry, so any downturn in life-sciences spending, tighter drug-industry budgets, or pharma R&D pullbacks would hit it more than a diversified software vendor. The CRM transition itself carries execution risk, and unwinding its historical relationship with Salesforce introduces competitive dynamics, as Salesforce and others could target the same customers. Regulatory change in the drug industry, biotech funding cycles, and consolidation among pharma customers can affect demand. AI is an opportunity but also a competitive threat if rivals or in-house tools erode Veeva's advantages. Currency swings and stock-based compensation are additional considerations. Analysts expect growth to ease to about 14% this fiscal year and about 11% next. Overall, Veeva is a strong business, but its premium price leaves limited room for disappointment.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell RLX or VEEV; figures are approximate and dated (as of November 2026). Verify current data before investing.